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Decreased endothelin receptor B expression in large primary
uveal melanomas is associated with early clinical metastasis and
short survival
SL Smith*,1, BE Damato2, AGM Scholes3, J Nunn4, JK Field4 and J Heighway1
1Gene Function Group, Roy Castle International Centre for Lung Cancer Research, 200 London Road, Liverpool L3 9TA, UK; 2Ocular Oncology Service, St Paul’s
Eye Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK; 3Unit of Ophthalmology, Department of Medicine, University of Liverpool, Liverpool
L69 3BX, UK; 4Molecular Genetics and Oncology Group, Clinical Dental Sciences, University of Liverpool L69 3BX, UK
The most devastating aspect of cancer is the metastasis of tumour cells to organs distant from the original tumour site. The
major problem facing oncologists treating uveal melanoma, the most common cancer of the eye, is metastatic disease. To
lower mortality, it is necessary to increase our understanding of the molecular genetic alterations involved in this process.
Using suppression subtractive hybridisation, we have analysed differential gene expression between four primary tumours from
patients who have developed clinical metastasis and four primary tumours from patients with no evidence of metastasis to
date. We have identified endothelin receptor type B as differentially expressed between these tumours and confirmed this
observation using comparative multiplex RT – PCR. In a further 33 tumours, reduced endothelin receptor type B expression
correlated with death from metastatic disease. Reduced expression also correlated with other known prognostic indicators,
including the presence of epithelioid cells, chromosome 3 allelic imbalance and chromosome 8q allelic imbalance. Endothelin
receptor type B expression was also reduced in four out of four primary small cell lung carcinomas compared to normal
bronchial epithelium. We also show that the observed down-regulation of endothelin receptor type B in uveal melanoma was
not due to gene deletion. Our findings suggest a role for endothelin receptor type B in the metastasis of uveal melanoma and,
potentially, in the metastasis of other neural crest tumours.
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Uveal melanoma (UM) is the most common primary intra-ocular
malignancy in adults, affecting approximately six people per
million of the population per year. Approximately 50% of all
patients with uveal melanoma die of metastatic disease (Damato
et al, 1996), despite successful treatment of the primary tumour.
The main clinical features associated with poor survival are largest
basal tumour diameter (LBTD), ciliary body involvement and
extra-scleral extension. Tumours showing rapid regression follow-
ing radiotherapy are also significantly more likely to metastasise
(Glynn et al, 1989). Histologically, the most important factors asso-
ciated with metastatic disease are the presence of epithelioid cells
and microvascular patterns, such as closed loops (Folberg et al,
1993; 2001; Ma¨kitie et al, 1999).
Uveal melanomas tend to develop characteristic somatic muta-
tions, particularly a loss of one copy of chromosome 3 (i.e.
monosomy 3) and gains in chromosome 8q copy number
(Prescher et al, 1996; Sisley et al, 1997; White et al, 1998; Scholes
et al, 2001). These aberrations show a positive correlation with a
poor prognosis for survival. Monosomy 3 shows a highly signifi-
cant correlation with metastasis (Prescher et al, 1996; Sisley et al,
1997; White et al, 1998; Scholes et al, 2001). Prescher et al (1996)
reported metastases from 17 out of 30 (57%) tumours with
monosomy 3 compared to none out of 24 (0%) patients without
monosomy 3, after a median follow-up of 3.4 years. The signifi-
cant correlation of changes to chromosome 3 with metastasis
suggests that genes on this chromosome may be involved in the
metastasis of uveal melanoma. However, there have been few
molecular genetic studies of uveal melanoma and there is very
little information about the involvement of specific genes, on
chromosome 3 or other chromosomes, in the progression to
metastasis.
To identify genes involved in uveal melanoma metastasis we
have performed suppression subtractive hybridisation (SSH). Using
this technique, we have compared gene expression patterns
between primary uveal melanomas with changes to chromosome
3, from patients with clinically evident metastasis, and melanomas
without alterations to chromosome 3, from patients that have
shown no evidence of metastatic disease (and whose tumours have
favourable clinical and histological features). We describe here the
identification of endothelin receptor type B (EDNRB) as a gene
that is differentially expressed between primary uveal melanomas
of different metastatic status and demonstrate the differential
expression of EDNRB in a wider uveal melanoma series. We also
show that EDNRB expression correlates with known predictive
factors for survival and with the incidence of metastatic disease.
Finally, we demonstrate that the down-regulation of EDNRB is
not due to homozygous gene deletion.
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MATERIALS AND METHODS
Patients and samples
Tumour and blood samples were obtained for experimental
purposes. Informed consent was obtained from all patients,
and the study approved by the Liverpool Research Ethics
Committee. A sample of fresh tumour tissue, approximately
2 – 3 mm in diameter, was snap-frozen in liquid nitrogen. The
remaining tumour was formalin fixed, paraffin-embedded and
processed for routine pathological studies. Histological and clin-
ical data were recorded in a computerised patient database.
Allelic imbalance data was obtained by PCR-based microsatellite
analysis using 10 microsatellite markers on the p and q arms of
chromosome 3 (Nunn et al, manuscript in preparation). Allelic
imbalance was recorded for informative markers if the intensity
of a tumour allele was reduced by at least 30% relative to
normal DNA. RNA samples from small cell lung carcinoma
(SCLC) patients were generated as part of a wider, ethically
approved, concurrent gene expression study being undertaken
at the Roy Castle Centre.
Uveal melanomas were obtained from 41 patients, after
primary treatment by enucleation (32 patients) or trans-scleral
local resection (nine patients). The patients comprised 27 males
and 14 females with a mean age of 64.1 years (range 29 – 85).
The largest basal tumour diameter, measured by ultrasono-
graphy, averaged 16 mm (range 9.7 – 20.7) and the thickness
averaged 9.2 mm (range 4 – 15). The ciliary body was involved
in 23 eyes. Histological examination showed epithelioid cells
in 28 tumours and closed loops in 27 tumours. The follow-
up ranged to 4.28 years (mean 1.29, median 0.87). Metastatic
disease occurred in 12 patients. Sixteen patients died. Twelve
of these died of metastatic disease, with the other four deaths
attributed to bronchial carcinoma, heart failure, brain haemor-
rhage, and myocardial infarction. Allelic imbalance at ten loci
on chromosome 3 (indicating probable monosomy 3) was seen
in 22 tumours and 21 tumours showed allelic imbalance at
position 8q24.1.
RNA and DNA extraction
Total RNA was extracted, from 20620 mm sections of the
frozen tumour samples, using TRIzol reagent (Invitrogen, Pais-
ley, UK), following the manufacturer’s protocol. RNA was run
on formaldehyde agarose gels and on an Agilent 2100 Bioanaly-
ser RNA chip (Agilent Technologies, Stockport, UK), to confirm
its integrity. DNA was extracted from blood and 20620 mm
frozen tumour sections using standard procedures (Liloglou et
al, 1997).
Suppression subtractive hybridisation (SSH)
Double stranded cDNA was prepared from 2 mg of total RNA
using the SMARTTM PCR cDNA synthesis kit (Clontech, Cowley,
Oxford, UK), following the manufacturer’s protocol. SSH was
performed using the PCR-SelectTM cDNA subtraction kit (Clon-
tech), again, following the manufacturer’s recommended
protocol. The resulting subtracted libraries were cloned into
pCR1-Blunt II-TOPO1 TA cloning vector (Invitrogen) and trans-
formed into One Shot1 TOP10 competent E. coli cells. Colonies
from the subtracted libraries were randomly picked and grown in
96-well liquid cultures. Bacterial plasmids were isolated using the
Qiagen Plasmid kit (Qiagen, Crawley, Sussex, UK), sequenced
with T7 reverse primer, using the ABI PRISM1 BigDye1 Termi-
nator Cycle Sequencing Ready Reaction Kit (Perkin Elmer,
Warrington, UK), and run on an ABI 377 sequencer (Perkin
Elmer).
Comparative, multiplex RT – PCR
Expression of the endothelin receptor type B gene was investigated
by comparative multiplex RT – PCR (cmRT – PCR). Reverse tran-
scription was performed with a Reverse Transcription system kit
(Promega, Southampton, UK), from 1 mg of total RNA, in a
20 ml synthesis. PCR reactions containing 1 ml of cDNA, four
primers (0.5 mg each of the control and test gene primer pairs),
16Taq reaction buffer (Roche, Lewes, East Sussex, UK), 200 mM
dNTPs (Roche) and 1 unit of Taq polymerase (Roche), in a total
of 50 ml, were assembled and cycled 30 times in a PE Applied
Biosystems GeneAmp PCR System 9700 machine at 588C for
1 min, 748C for 1 min and 948C for 1 min, with an initial dena-
turation of 2 min at 948C and a final cycle of 588C for 1 min,
748C for 3 min. Reaction products were visualised on 2.5% agarose
gels run in TAE, and analysed quantitatively by Agilent 2100 Bio-
analysis using a DNA 500 test kit (Agilent Technologies), as direc-
ted. Control primers to HPRT (hypoxanthine-guanine
phosphoribosyl transferase, HPRTF 5’-ACA CTT CGT GGG GTC
CTT TTC A-3’ and HPRTR 5’-GCT GAC CTG CTG GAT TAC
ATC A-3’) were used in uveal melanoma samples, and to hypothe-
tical protein KIAA0228 (Accession number: D86981, HEF 5’-GAA
CTG TGT GCA CTC CTA TTT G-3’ and HER 5’-CCG TGC
CAA ATA CAC TGC ATG T-3’) which is levelly expressed in lung
carcinomas, compared to matched normal lung tissue, in SCLCs.
Primers to EDNRB were EDF 5’-GGA TGA AGC AAG CAG
ATT CGC A-3’ and EDR 5’-TGC ATG CGA AAC GGT CCC
AAT A-3’ and amplified a 383 bp product between exons 1 and
3. Primers were designed to be cDNA specific, and were confirmed
as such by the absence of any specific amplification in a control
genomic DNA reaction. Comparative multiplex RT – PCR involves
the co-amplification, by PCR, of control and test sequences from
cDNA, in the same reaction. Levels of a particular mRNA are
compared between different samples, by relating expression levels
of the test gene to those of a control gene, the expression of which
is constant between samples.
Comparative, multiplex PCR
Tumours were screened for amplification of the EDNRB gene by
comparative, multiplex PCR (cmPCR). cmPCR reactions contain-
ing four primers (0.5 mg each of the control and test primer
pairs), 16Taq reaction buffer, 200 mM dNTPs (Roche) and 1 unit
of Taq polymerase, in a total of 50 ml, were assembled and cycled
30 times in a PE Applied Biosystems GeneAmp PCR System 9700
machine at 588C for 1 min, 748C for 1 min and 948C for 1 min,
with an initial denaturation of 2 min at 948C and a final cycle of
588C for 1 min, 748C for 3 min. Test primers to the EDNRB gene
were EDF-G 5’-CTA CAC AGC ACT TCA GCT ACT G-3’ and
EDR-G 5’-AAT GCA GCC ACA ACT CCA TGA G-3’. Control
primers were to the b-globin gene (GLOF 5’-GCA GCT GAG
TAG CAA GGA TG-3’ and GLOR 5’-ATC TGC ACA CTT
GAG GGC ATG-3’. Products were visualised on 2.5% agarose
gels.
Statistical analyses
Spearman’s correlation coefficient was used to assess the relation-
ship between EDNRB expression and LBTD, both of which were
continuous, non-parametric variables. The Mann – Whitney test
was used to examine how EDNRB expression was associated with
ciliary body involvement, epithelioid cells, closed loops, allelic
imbalance on chromosome 3 and allelic imbalance on chromosome
8q. All P values were two-sided. A P value of 40.05 was taken to
indicate statistical significance.
Survival of patients according to the level of EDNRB expression
was plotted according to the Kaplan – Meier method. Association
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between metastatic death and the level of EDNRB expression was
assessed by Cox univariate analysis.
RESULTS
Identification of EDNRB as differentially expressed in
metastatic uveal melanoma
In order to identify genes involved in the metastasis of uveal mela-
noma, we compared gene expression patterns between primary
uveal melanomas from patients with and without clinically evident
metastasis. Using SSH, cDNA pooled from four primary UM with
monosomy 3, that had detectable metastases was compared with
cDNA pooled from four UM without monosomy 3, and with no
evidence of metastasis, within at least 3 years of diagnosis of the
primary tumour. Subtractions were performed in both forward
and reverse directions for the pooled sample pairs. That is, cDNA
from each pool was used as tester and driver in two separate
experiments, in order to identify cDNAs that were either over-
or under-represented in the metastatic samples. Approximately
400 clones were obtained in each of the forward and reverse
libraries. Of these, a total of 180 have been successfully sequenced,
to date. Twenty of the sequenced clones (10 forward and 10
reverse) were prioritised for further investigation on the basis of
several criteria, including a known role in metastasis, location to
chromosomes 3 or 8 and the frequency of the sequence in the
library. One of the prioritised clones identified in the reverse
library (i.e. the library containing sequences under-represented in
the metastasising tumours) matched part of the EDNRB gene as
determined by a standard BLAST (Basic linear alignment search
tool) search.
EDNRB expression in uveal melanoma
CmRT – PCR was used to verify the differential expression of
EDNRB in the tumours used in SSH. Levels of EDNRB, relative
to the control gene HPRT, were higher in the four primary
tumours from patients with no evidence of metastasis compared
to the four primary tumours from patients with clinically evident
metastases (Figure 1). No product was present in a negative
control lane, nor in a genomic DNA control (see Figure 2), indi-
cating that the primers are cDNA specific. Agilent Bioanalysis of
the cmRT – PCR results allowed quantification of the results (data
not shown). The relative peak heights of each product were used
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1             2            3             4            5             6            7             8         -ve
— EDNRB
— HPRT
603 —
310 —
281,271 —
234 —
194 —
Figure 1 Comparative, multiplex RT – PCR amplification of EDNRB and the control gene HPRT in primary uveal melaonomas from patients with no
evidence of metastasis (non-met) and patients with clinically evident metastasis (met).
9      10     11     13     15      16     18     19    20     5      22     23     6      7      27     28
— EDNRB
— HPRT
— EDNRB
— HPRT
603 —
310 —
194 —
603 —
310 —
194 —
603 —
310 —
194 —
30      8      32     36     40     41     12     14      1      17      2       3       4      25     26     29
31    33     34     21     24     39     35     37    38     G     -ve
— EDNRB
— HPRT
Figure 2 Comparative, multiplex RT – PCR of EDNRB and HPRT in uveal melanomas. G: genomic. – ve: Negative control. Numbers correspond to the
tumour details in Table 1.
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to calculate the percentage expression of EDNRB relative to HPRT
(see Table 1). The level of EDNRB in the four tumours that had
metastasised was between 4- and 50-fold less than the level of
HPRT, whereas the level of EDNRB in the tumours that had
no evidence of metastasis was approximately equal to the level
of HPRT or greater (up to three-fold higher) than the level of
HPRT.
Association of EDNRB expression with other predictive
factors for survival
To determine whether EDNRB expression could be correlated to
metastatic disease and to other prognostic indicators, such as clin-
ico-pathological variables and genomic alterations (specifically
chromosome 3 loss), we analysed EDNRB expression in a further
33 uveal melanomas by cmRT – PCR (Figure 2). The relative
percentages of EDNRB, compared to HPRT in each tumour, as
determined by Agilent Bioanalysis are shown in Table 1, together
with clinico-pathological data, genomic alterations and evidence
of metastatic disease.
The relative expression of EDNRB in the 33 tumours showed a
non-normal distribution, with a median of 27.4% (range 4.4 –
76.4%). A relative percentage of EDNRB of less than 27.4% was
defined as reduced expression. This cut-off point was selected a
priori according to the median value. Reduced EDNRB was asso-
ciated with allelic imbalance on chromosome 3 (P=50.001),
allelic imbalance on chromosome 8q (P=50.001) and the presence
of epithelioid cells (P=0.014). EDNRB expression did not correlate
with LBTD (P=0.142), ciliary body involvement (P=0.07) or the
presence of microvascular loops (P=0.07). Down-regulation of
EDNRB was correlated with metastatic death (Figure 3, Cox
univariate analysis, P=0.05).
EDNRB expression in SCLC
To determine whether EDNRB mRNA levels are reduced in SCLC
we investigated expression of the gene by cmRT – PCR. Expression
of EDNRB was analysed in cDNA derived from four primary
SCLCs and in normal cDNA from the same patient. In all four
cases the tumour cDNA showed reduced levels of EDNRB (relative
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Table 1 Details of uveal melanomas
Tumour Cell Mv C3 C8 EDNRB Follow-up
number CB type loops? LBTD Met AI AI (%) (days)
1 Yes S No 18 No No No 66.4 2
2 No S No 17 No No No 76.4 203
3 Yes S No 13 No No No 33.1 2
4 No S No 13 No No No 46.7 887
5 No M Yes 19 Yes Yes Yes 5.6 245
6 Yes M Yes 14 Yes Yes Yes 8.1 63
7 Yes M Yes 17 Yes Yes Yes 10.1 637
8 Yes M Yes 16 Yes Yes Yes 7.2 368
9 Yes M Yes 12 Yes Yes No 14.9 461
10 Yes M Yes 20 Yes Yes No 20.9 470
11 Yes M Yes 19 Yes Yes Yes 10.6 698
12 No M Yes 16 No No No 47.4 1563
13 Yes E Yes 20 Yes Yes Yes 44.5 1139
14 No S No 17 No No No 44.7 2
15 Yes M Yes 18 No Yes Yes 12.0 926
16 No M Yes 20 Yes Yes Yes 4.4 964
17 No M Yes 12 No No No 47.0 552
18 No E Yes 15 Yes Yes Yes 6.8 1397
19 Yes M Yes 18 No Yes Yes 15.2 2
20 Yes M Yes 13 No Yes Yes 7.5 2
21 No M Yes 12 No No No 27.4 1295
22 Yes M Yes 18 No Yes Yes 8.0 1195
23 Yes M Yes 16 Yes Yes Yes 13.11 316
24 No S No 17 No No No 44.6 1297
25 No E No 18 No No No 64.2 9
26 No S No 13 No No No 43.8 58
27 Yes E Yes 19 Yes Yes Yes 9.2 947
28 Yes M No 20 No Yes Yes 9.7 638
29 No S No 9 No No No 26.8 12
30 Yes M No 15 No Yes Yes 43.5 819
31 Yes M Yes 10 No No No 54.6 35
32 Yes M Yes 15 No Yes Yes 39.4 2
33 No S No 12 No No No 30.9 938
34 No M Yes 15 No Yes Yes 33.7 1038
35 Yes S No 11 No No No 38.4 2
36 Yes M Yes 15 No Yes Yes 24.1 13
37 No S Yes 13 No No No 63.5 2
38 Yes S No 14 No No No 48.4 10
39 No S No 12 No No No 30.7 2
40 Yes M Yes 14 No Yes Yes 10.7 2
41 No M Yes 9 No Yes Yes 23.6 134
Mv=microvascular loops; LBTD=largest basal tumour diameter (mm); S=spindle; M=mixed; E=epithelioid; CB=ciliary body involve-
ment; AI=allelic imbalance; Met=metastasis diagnosed. Tumours used in SSH above dotted line.
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to the control gene KIAA0228), when compared with cDNA from
histologically normal lung tissue in the same patient (Figure 4).
Loss of EDNRB expression in uveal melanoma is not due to
gene deletion
To investigate the underlying mechanism for reduced EDNRB
expression in uveal melanoma, we examined whether the EDNRB
gene on chromosome 13q22 was homozygously deleted. cmPCR
was used to compare EDNRB copy number to that of the b-globin
gene localised on chromosome 11p15. Reactions were balanced in
normal DNA, from blood samples of patients with UM, to give
approximately equal amounts of test and control products. The
same ratio of control and test primers was then used in tumour
samples. DNA from nine tumours was investigated. None of the
nine tumours analysed (including four from patients with metasta-
sis and five from patients with no evidence of metastasis) showed
an imbalance between the test and control PCR products,
compared to normal DNA from the same patient (data not
shown).
DISCUSSION
Previously, there have been very few investigations into the invol-
vement of specific genes in the metastasis of uveal melanoma.
Using suppression subtractive hybridisation, we have compared
gene expression patterns between a pool of primary uveal melano-
mas from patients that have developed clinical metastases and a
second pool of primary uveal melanomas from patients that have
shown no evidence of metastasis. We have shown that endothelin
receptor type B expression is lower in primary uveal melanomas
of high metastatic genotype and phenotype than in tumours with
no evidence of metastatic disease; an observation that has been
validated in a wider series of tumours, using comparative multiplex
RT – PCR.
In this study, reduced EDNRB expression correlated with
monosomy 3 (as determined by allelic imbalance at multiple, chro-
mosome spanning markers), changes to chromosome 8q (at
position 24.1) and the presence of epithelioid cells. Reduced
expression also correlated with metastasis-related death. The results
of our analysis are significant because they show EDNRB down-
regulation to be statistically related to known predictive factors
and, indeed, to metastatic disease. EDNRB expression did not
correlate with largest basal tumour diameter. This is likely due to
the fact that there were few small tumours in our sample, most
small tumours having been treated by phototherapy or radio-
therapy. Two patients developed metastatic disease despite having
a normal EDNRB level. Mutations within the EDNRB gene, or
within other genes in linked pathways, may explain this observa-
tion. Several patients with low EDNRB levels have not developed
clinical metastases to date. Since uveal melanoma has a propensity
for late clinical metastasis, sometimes up to 15 or 20 years after
enucleation (Jensen, 1982), it is possible that these tumours
have micrometastases even if no clinically evident metastases are
apparent at the present time.
Metastasis describes the process by which cancerous cells escape
the primary tumour, enter the bloodstream or lymphatics (in other
cancers, but not in uveal melanoma) and form micrometastases at
other sites in the body. These clonal lesions may subsequently grow
into secondary tumours. Whether EDNRB down-regulation is asso-
ciated with the initiation of metastasis (at the point where single
cells escape the primary tumour), the survival of the detatched cells
in the bloodstream or whether its down-regulation is associated
with the establishment and growth of the secondary tumour
remains to be determined. It is important to point out that due
to the lack of small tumours in this study, our observations
concerning EDNRB down-regulation and metastasis cannot be
applied to small T1 and T2 uveal melanomas. Furthermore, we
cannot determine at which stage EDNRB down-regulation occurs.
Studies using smaller tumours, and uveal melanoma cell lines from
tumours at different stages of progression, would go some way to
determining at which stage down-regulation of EDNRB occurs.
It is also important to determine whether down-regulation of
EDNRB occurs as a result of direct genetic damage (point muta-
tions of control regions or the gene sequence itself, chromosomal
translocations, gene deletions) or whether its expression is altered
due to damage to other genes at higher points in control pathways.
In a study by Aalto et al (2001), 50% of metastases from primary
uveal melanomas were shown to exhibit losses in 13q, by compara-
tive genomic hybridisation (CGH). We therefore investigated
whether the observed reduced EDNRB levels were due to deletion
of the EDNRB gene at 13q22. We did not detect any changes to the
EDNRB gene copy number in any of nine tumours analysed.
Whilst homozygous loss (HL) may be difficult to detect in primary
tumour material, given that all the tumours used had tumour cell
percentages in excess of 90%, if HL was present we would have
expected the cmPCR to detect that loss. It would therefore appear
that an alternative mechanism to gene deletion leads to the reduced
expression of EDNRB. EDNRB is encoded by a gene that contains
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Figure 4 Comparative multiplex RT – PCR of EDNRB and the control gene KIAA0228 in SCLCs. N: cDNA from matched normal tissue. T: Tumour
cDNA.
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a 5’ CpG island encompassing the transcriptional regulatory region.
This region has been reported to be methylated in 70% of prostate
cancer samples (including primary tissue and cell lines) analysed by
Nelson et al (1997) but unmethylated in normal tissues. CpG
island methylation of the EDNRB gene promoter may therefore
be responsible for the reduction in EDNRB levels in metastatic
uveal melanoma.
Down-regulation of EDNRB occurs in other cancers. A compar-
ison of EDNRB in four cutaneous melanoma cell lines originating
from metastases, with three cell lines from primary tumours has
shown the metastatic tumours to be characterised by low level
expression of EDNRB (Kikuchi et al, 1996). Similarly, Grant et al
(1997) have reported that human prostate cancer progression to
metastases is accompanied by a reduction in EDNRB levels. In this
study, we have also found reduced EDNRB levels in four out of
four SCLCs, relative to matched normal lung control tissue. Similar
to uveal melanoma, SCLC are neural crest derived tumours that
exhibit changes to chromosome 3 (Sundaresan et al, 1992) and
have a particularly aggressive clinical course, with frequent wide-
spread metastases at diagnosis. However, not all studies have
produced consistent results. For example, using immunohisto-
chemistry and RT – PCR, Demunter et al (2001) reported
increased EDNRB levels in metastatic cutaneous melanomas as
compared with primary melanomas. The role of EDNRB in both
uveal melanoma and other cancers, therefore, remains unclear.
In summary, we have shown that EDNRB shows reduced
expression in large primary uveal melanomas of high metastatic
genotype and phenotype, and in small cell lung cancer. The exact
role of EDNRB in metastasis, the mechanism responsible for
reduced expression and whether its down-regulation drives the
metastatic process remain to be determined. EDNRB is a 7-span
transmembrane G-protein coupled receptor, and since
membrane-located receptors (mainly G-protein coupled receptors)
constitute approximately 45% of all therapeutic drug targets
(Drews, 2000), if a role in metastasis is proven, EDNRB, may be
a good candidate for targeted therapy.
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